Monoclonal antibody holds promise of reducing learning, memory problems in schizophrenia

January 26, 2016, Medical College of Georgia at Augusta University
Monoclonal antibody holds promise of reducing learning, memory problems in schizophrenia
Dr. Brian J. Miller. Credit: Augusta University Senior Photographer Phil Jones

Chronic learning and memory problems that plague patients with schizophrenia may have a worthy foe in a monoclonal antibody that also holds promise in the fight against cancer and is already used to treat a rare disorder similar to lymphoma, researchers say.

Siltuximab directly targets interleukin 6, or IL-6, a protein and cytokine that is a key regulator of , which is often elevated in patients with schizophrenia, said Dr. Brian J. Miller, psychiatrist and schizophrenia expert in the Department of Psychiatry and Health Behavior at the Medical College of Georgia at Augusta University.

There's mounting evidence from researchers such as Miller that inflammation has a pathological role, including contributing to impaired cognition, in as many as 40 percent of patients with schizophrenia.

The new MCG study, funded by the nonprofit Stanley Medical Research Institute, is exploring the powerful anti-inflammatory drug's ability to improve cognition in stable patients with schizophrenia or related schizoaffective disorder whose blood tests show evidence of elevated inflammation.

Researchers are enrolling 30 patients; half will receive three infusions of siltuximab over nine weeks in addition to their usual antipsychotic drug regimen and half a placebo infusion.

"Cognitive impairment in schizophrenia is a huge area of unmet need that persists despite treatment with our existing antipsychotic medications and is a real driver of overall level of functioning and quality of life," Miller said.

Many patients with schizophrenia, even those considered well controlled, have problems with memory, attention, learning, and executive function, which means they often have problems functioning.

"If somebody calls you about a job interview and you can't remember the 10 digits of the phone number long enough to write it down, it's hard to call back to set up that job interview," Miller said. He likens it to having a chronic flu that makes it super tough to concentrate.

In a previous study of 64 patients, higher blood levels of the cytokine IL-6 was a significant predictor of greater cognitive impairment. And Miller's small pilot study of the anti-inflammatory arthritis drug tocilizumab, which targets the IL-6 receptor, found some "robust" improvements in cognition. He's hopeful that directly targeting IL-6 with the new drug will yield even more benefit to patients.

High IL-6 levels have been correlated with a smaller hippocampus, a center for learning and memory in the brain, as well as other psychiatric symptoms. Keeping IL-6 from binding with its receptor could be particularly beneficial since binding can form and activate a complex that ultimately boosts IL-6 signaling, which generally means more inflammation, Miller said. He notes that IL-6 can both boost and reduce inflammation.

Anti-inflammatory medications are not yet considered standard treatment for patients with schizophrenia, Miller said. However, his own findings and others' about the role of inflammation at least in some patients, means Miller often measures levels of C-reactive protein as an inflammatory marker in those not responding well to traditional drug therapy. He often also prescribes anti-inflammatory agents for patients with increased C-reactive protein levels. C-reactive protein levels are a cheaper inflammatory marker to measure than the research protocol he's using to measure IL-6 levels. In fact, cardiologists already use C-reactive as a measure of cardiovascular risk in their patients. That cardiovascular benefit could be good for patients with schizophrenia as well since some antipsychotics used to treat their condition come with side effects that include weight gain and additional cardiovascular risk.

Miller's also hopeful that by directly targeting IL-6, siltuximab has no "off-target" effects, in contrast to more common anti-inflammatory agents such as aspirin and the arthritis drug Celebrex. If the drug works as well as he suspects it will, it also will provide more evidence that inflammation is part of what's driving cognitive dysfunction in these patients, Miller said.

Cytokines such as IL-6 can directly and indirectly modulate neurotransmission, which may contribute to an episode of worsening psychosis, Miller said. IL-6 levels also have been shown to be elevated in some with schizophrenia, and laboratory studies have provided similar support. In fact, when a pregnant woman is infected with any number of agents, from viruses to parasites, at a key point in her baby's development, it confers a two- to threefold risk of schizophrenia on her offspring, Miller said. Patients with autoimmune disorders also are at increased risk of schizophrenia and vice versa.

The Maryland-based Stanley Medical Research Institute supports research in and bipolar disease.

Explore further: Will blocking IL-17A help treat kidney disease?

Related Stories

Will blocking IL-17A help treat kidney disease?

January 22, 2016
Many different diseases and insults can injure kidneys, resulting in kidney failure. Some autoimmune diseases damage glomeruli (the 'filtering units' of the kidney), while problems with the tubules (for example, impaired ...

Potential therapeutic targets identified for multiple sclerosis

January 25, 2016
Treatment of multiple sclerosis (MS) and other inflammatory diseases may benefit by new findings from a study that identified potential therapeutic targets for a devastating disease striking some 2.3 million people worldwide.

Scientists prevent, reverse diabetes-related kidney destruction in animal model

December 28, 2015
Diabetes is the leading cause of kidney failure, and scientists have found that infusing just a small dose of a cytokine, thought to help cause that failure, can instead prevent or reverse it.

Researchers pursue red flag for schizophrenia relapse

August 6, 2012
Blood levels of a protein that helps regulate inflammation may also serve as a red flag for relapse in some schizophrenia patients, researchers said.

Study shows link between inflammation in maternal blood and schizophrenia in offspring

July 8, 2014
Maternal inflammation as indicated by the presence in maternal blood of early gestational C-reactive protein—an established inflammatory biomarker—appears to be associated with greater risk for schizophrenia in offspring, ...

Experimental mood induction impacts IL-18 levels

December 23, 2015
(HealthDay)—Experimental mood induction changes interleukin (IL)-18 levels and is associated with changes in central opioid neurotransmission, according to a study published recently in Molecular Psychiatry.

Recommended for you

Kids show adult-like intuition about ownership

May 22, 2018
Children as young as age three are able to make judgements about who owns an object based on its location, according to a study from the University of Waterloo.

Age-related racial disparity in suicide rates among US youth

May 21, 2018
New research suggests the suicide rate is roughly two times higher for black children ages 5-12 compared with white children of the same age group. The study, funded by the National Institute of Mental Health (NIMH), appears ...

Schizophrenia more prevalent away from green spaces

May 21, 2018
People who grew up without green spaces are 50 per cent more likely to develop schizophrenia compared with those who grew up surrounded by greenery.

Cannabis—it matters how young you start

May 18, 2018
Canadian researchers find that boys who start smoking pot before 15 are much more likely to have a drug problem at 28 than those who start at 15 or after.

Long legs turn women's heads, arm length immaterial: study

May 16, 2018
Labouring over the age-old question "What do women look for in men?", scientists added an item to the list Wednesday: legs slightly longer than average, with a good shin-to-thigh ratio.

Elevated homocysteine identified as metabolic risk factor for neurodegenerative diseases

May 16, 2018
The amino acid homocysteine occurs naturally in the human body, generated as a byproduct of methionine metabolism. Genetic diseases or an imbalanced diet, with too much red meat or deficiencies in B vitamins and folic acid, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.